
hapabapa
- argenx (NASDAQ:ARGX) is down ~7% in Monday trading after the U.S. FDA issued an alert on a potential signal of serious risks associated with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase).
- The agency says that the treatment, used for generalized myasthenia gravis